Fascial Sarcoma – Causes, Symptoms and Treatment

What is a Fascial Sarcoma?

A fascial sarcoma is a rare malignant tumor (sarcoma) that originates in the fascia – the dense connective tissue sheaths that surround and support muscles, organs, and other structures throughout the body. As a type of soft tissue sarcoma, it belongs to the group of malignant tumors arising from mesenchymal tissue. Soft tissue sarcomas as a whole are uncommon, accounting for less than 1% of all malignant tumors in adults.

Causes and Risk Factors

The exact cause of fascial sarcoma is often unclear. However, several factors are known to increase the risk:

• Genetic predisposition: Hereditary conditions such as Li-Fraumeni syndrome or neurofibromatosis type 1 are associated with a higher risk of developing sarcomas.
• Previous radiation therapy: Prior radiotherapy to a body region can lead to a radiation-induced sarcoma years or even decades later.
• Chronic lymphedema: Persistent lymphatic obstruction, for example following breast cancer surgery, may contribute to sarcoma development.
• Chemical exposure: Contact with certain chemicals such as dioxins or vinyl chloride has been discussed as a potential risk factor.
• Trauma: In rare cases, a link to prior injury has been suggested, although a direct causal relationship has not been conclusively established.

Symptoms

The symptoms of a fascial sarcoma are often nonspecific at first, which can make early diagnosis challenging:

• A painless or tender soft tissue swelling or a palpable lump, often located deep within the tissue
• A gradually enlarging mass over weeks or months
• Pain or pressure if the tumor compresses adjacent nerves or blood vessels
• Reduced range of motion in the affected body region
• General symptoms such as fatigue and unintentional weight loss, more commonly seen in advanced disease

Particular attention should be paid to swellings larger than 5 cm, deep-seated masses, or rapidly growing lumps, as these features raise suspicion for a sarcoma and warrant prompt medical evaluation.

Diagnosis

Diagnosing a fascial sarcoma requires a careful combination of clinical examination, imaging studies, and tissue sampling:

Imaging

• MRI (Magnetic Resonance Imaging): The preferred method for assessing the extent, location, and relationship of the tumor to surrounding structures.
• CT (Computed Tomography): Used to evaluate possible bone involvement and to detect distant metastases, especially in the lungs.
• PET-CT: May be used to assess tumor metabolic activity and for staging purposes.

Biopsy

The definitive diagnosis is established through a biopsy, in which a tissue sample is obtained and examined histologically and immunohistochemically. The biopsy should be planned and performed at a specialized sarcoma center to ensure that subsequent surgical treatment is not compromised.

Staging

Staging – the process of determining how far the tumor has spread – follows internationally recognized classification systems such as the AJCC/UICC system and takes into account tumor size, depth of invasion, histological grade, and the presence of lymph node or distant metastases.

Treatment

Treatment of fascial sarcoma depends on the stage, location, histological grade, and the overall health of the patient. Management is ideally carried out by a multidisciplinary team at a specialized sarcoma center.

Surgery

Surgical resection with adequate tumor-free margins (R0 resection) is the cornerstone of treatment. The goal is complete tumor removal while preserving the function of the affected limb or body region (limb-sparing surgery) whenever possible.

Radiation Therapy

Radiation therapy is often used as an adjunct to surgery – either before the operation (neoadjuvant) to reduce tumor size, or after surgery (adjuvant) to lower the risk of local recurrence, particularly in high-grade tumors or when surgical margins are close.

Chemotherapy

Chemotherapy plays a role primarily in high-grade or metastatic fascial sarcomas. Standard agents include doxorubicin and ifosfamide. Newer targeted therapies and immunotherapy approaches are being investigated in clinical trials.

Follow-up Care

Regular follow-up examinations after completion of treatment are essential to detect any potential recurrence at an early stage. The frequency of follow-up visits is tailored to the individual risk profile of each patient.

Prognosis

The prognosis of a fascial sarcoma depends significantly on tumor size, histological grade, completeness of surgical resection, and the presence of metastases. Low-grade tumors that are completely resected without evidence of metastasis carry a considerably better prognosis than high-grade or metastatic forms. The 5-year survival rate varies substantially depending on the disease stage.

References

1. Gronchi A, Miah AB, Dei Tos AP et al. – Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2021; 32(11): 1348–1365.
2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds.) – WHO Classification of Tumours of Soft Tissue and Bone. 4th edition. IARC Press, Lyon, 2013.
3. Woll PJ, Reichardt P, Le Cesne A et al. – Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma. The Lancet Oncology, 2012; 13(10): 1045–1054.